- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Taxol (paclitaxel), Radiotherapy, Carboplatin, Gemcitabine
- Drug · Procedure
- Lead sponsor
- Leo W. Jenkins Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 12,417
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Durvalumab, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Methoxyamine, Pemetrexed, Radiation Therapy
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 34
- States / cities
- Buena Park, California • Duarte, California • Irvine, California + 27 more
- Conditions
- Sexual Dysfunction
- Interventions
- Multi-modality sexual dysfunction intervention
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine Phosphate, Ibrutinib, Obinutuzumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 352 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Major Depressive Diorder, Early Life Trauma
- Interventions
- Lumateperone 42 mg, Placebo
- Drug · Other
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Renal Anemia
- Interventions
- AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
- Drug
- Lead sponsor
- Kind Pharmaceuticals LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Pine Bluff, Arkansas • Riverside, California • Lone Tree, Colorado + 5 more
- Conditions
- Metastatic Malignant Solid Neoplasm
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Nivolumab
- Drug · Other · Biological
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
- Interventions
- AG-01 Compound
- Drug
- Lead sponsor
- A&G Pharmaceutical Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma, Non-Hodgkin, HIV Infections
- Interventions
- Peripheral blood stem cells
- Drug
- Lead sponsor
- Ribozyome
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Craniocervical Injuries
- Interventions
- Alar treatment with BMC using anterior approach
- Procedure
- Lead sponsor
- Regenexx, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Broomfield, Colorado
- Conditions
- Spinal Cord Injuries, Pressure Injuries
- Interventions
- pulsed wound irrigation (PWI), electrical stimulation (ES), electrical stimulation (ES) and pulsed wound irrigation (PWI)
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head and Neck Cancer, Advanced Head and Neck Cancer, Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- Duvelisib, Docetaxel
- Drug
- Lead sponsor
- Kartik Sehgal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Azithromycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 19
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Promyelocytic Leukemia With PML-RARA, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Alkylating Agent-Related Acute Myeloid Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Post-Transplant Lymphoproliferative Disorder, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Richter Syndrome, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Benign Neoplasm, Bone Marrow Transplantation Recipient, Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm
- Interventions
- Bone Marrow Transplantation, CliniMACS CD34 Reagent System, Peripheral Blood Stem Cell Transplantation
- Procedure · Device
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
- Interventions
- Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma
- Interventions
- total-body irradiation (TBI), thiotepa, fludarabine phosphate, melphalan, anti-thymocyte globulin, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
- Radiation · Drug · Biological + 2 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 19 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Dilated Cardiomyopathy
- Interventions
- Ixmyelocel-T, Vehicle Control
- Biological · Other
- Lead sponsor
- Vericel Corporation
- Industry
- Eligibility
- 18 Years to 86 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Cleveland, Ohio • Salt Lake City, Utah
- Conditions
- Small Cell Lung Cancer
- Interventions
- ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 12
- States / cities
- New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more
- Conditions
- Substance Use Disorder (SUD)
- Interventions
- continuing care app
- Device
- Lead sponsor
- Friends Research Institute, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Interventions
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
- Drug
- Lead sponsor
- Mundipharma Research Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
- Conditions
- Postoperative Complications, Plastic Surgery
- Interventions
- Photobiomodulation
- Device
- Lead sponsor
- Elixir MD Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California